Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
About Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Charite University, Berlin, Germany
2
Genentech, Inc.
1
Clinical Trials at Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
During the past decade, Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo. conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 5 clinical trials were completed, i.e. on
average, 500% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
2007-07-26
2011-11-30
Terminated
787
Risk Stratified Sequential Treatment for CD20-positive PTLD
2006-12-01
2015-07-01
Completed
152
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
2002-12-01
2011-10-01
Terminated
70
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
2011-12-06
2017-10-31
Completed
30
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
2012-09-03
2016-04-30
Terminated
415
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
2012-12-03
2017-05-31
Terminated
182
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
2013-06-10
2019-12-31
Completed
780
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
2013-08-14
2021-01-26
Completed
153
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo."
#1 collaborator was "Foundation Medicine, Inc." with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
According to Clinical.Site data, the most researched conditions in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo." are
"Gastric Cancer" (5 trials), "B-cell Lymphoma" (1 trials), "Breast Cancer" (1 trials), "Cancer of Unknown Primary Site" (1 trials) and "PTLD" (1 trials). Many other conditions were trialed in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo." in a lesser frequency.
Clinical Trials Intervention Types at Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
Most popular intervention types in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo." are "Drug" (9 trials). Other intervention types were less common.
The name of intervention was led by "Capecitabine" (3 trials), "Cisplatin" (3 trials), "Pertuzumab" (3 trials), "Placebo" (3 trials) and "5-Fluorouracil" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
The vast majority of trials in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo." are
9 trials for "All" genders.
Clinical Trials Status at Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
Currently, there are NaN active trials in "Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo., 0 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".